In 2006, Tokumo et al reported a progressed-death NSCLC patient with EGFR L858R/D761Y mutation, which was clinically reported to be resistance to Gefitinib treatment.[10] Subsequently, Balak et al reported that the EGFR D761Y mutation was a “novel secondary mutation” that appeared in a metastatic brain lesion after the acquisition of Gefitinib resistance published in clinical cancer research. Here, EGFR is linked to cancer.